EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

This study is building a European registry of patients with advanced non-small cell lung cancer (NSCLC — the most common type of lung cancer) to study how well liquid biopsies (blood-based tests called plasma molecular profiling) detect genetic changes in cancer DNA. The goal is to understand how these blood tests compare to standard tumor tissue testing to guide treatment decisions. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with locally advanced or metastatic NSCLC (stage IIIB/C or IV) that has not yet been treated for advanced disease - You are about to start first-line (initial) treatment for your advanced lung cancer - You are in reasonably good physical health (ECOG performance status 2 or lower) **You may NOT be eligible if...** - You have had another non-skin cancer within the past 5 years (early non-invasive cervical cancer is an exception) Talk to your doctor to see if this trial is right for you.